Altimmune to Participate in Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:

• Stifel 2025 Healthcare Conference
  Wednesday, November 12, 2025
  Fireside Chat at 10:00 a.m. ET

• Jefferies Global Healthcare Conference
  Thursday, November 20, 2025
  Fireside Chat at 9:30 a.m. GMT

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]

Media Contact:
Elliot Fox
Real Chemistry
[email protected]

This press release was published by a CLEAR® Verified individual.

You May Also Be Interested In

• Gray & Sons Jewelers Announces New Analysis on Professional Restoration and Luxury Watch Value
• Heinemann Launches Whole Book Comprehension by Bestselling Author Jennifer Serravallo
• 30 Greenberg Traurig Attorneys Recognized on Managing Intellectual Property's 2026 'IP Stars' List